Effects of SQ109 on QTc Interval in Healthy Subjects

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT01874314
First received: May 23, 2013
Last updated: March 20, 2014
Last verified: May 2013
  Purpose

This will be a single center, open label, crossover study to evaluate the safety and tolerability of multiple dose levels of SQ109.


Condition Intervention Phase
Tuberculosis
Drug: SQ109
Other: SQ109 Placebo
Drug: Moxifloxacin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:
  • Solicited and unsolicited adverse events, including symptoms, physical findings, laboratory testing, holter monitor and ECG changes for 300mg/day SQ109 [ Time Frame: Days 1-7 of each dosing period and 30 days after last dosing period. ] [ Designated as safety issue: Yes ]
  • Electrocardiogram and holter monitor data (QTc, T wave forms, QRS, RR and PR intervals) for 300mg/day SQ109 [ Time Frame: Days 1-7 of each dosing period and 30 days after last dosing period. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Solicited and unsolicited adverse events, including symptoms, physical findings, laboratory testing, holter monitor and ECG changes for 450mg/day SQ109 [ Time Frame: Days 1-7 of each dosing period and 30 days after last dosing period. ] [ Designated as safety issue: Yes ]
  • Pharmacokinetics of SQ109 at doses of 300 or 450mg/day; AUC0-, (Cmax), time to maximum concentration (Tmax), elimination rate constant, elimination half-life, clearance, volume of distribution, and urinary excretion [ Time Frame: Day 1 and Day 6 of each dosing period ] [ Designated as safety issue: No ]
  • Electrocardiogram and holter monitor data (QTc, T wave forms, QRS, RR and PR intervals) for 450mg/day SQ109 [ Time Frame: Days 1-7 of each dosing period and 30 days after last dosing period. ] [ Designated as safety issue: Yes ]

Enrollment: 0
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SQ109 450 mg
Single daily dose of oral 450mg SQ109 for 7 days.
Drug: SQ109
300mg or 450mg of SQ109 administered orally, once daily for 7 days.
Active Comparator: Moxifloxacin
Single daily dose of oral 400mg moxifloxacin for 7 days followed by 7 days washout period.
Drug: Moxifloxacin
400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
Placebo Comparator: SQ109 Placebo
Single daily dose of oral SQ109 placebo for 7 days followed by 7 days washout period.
Other: SQ109 Placebo
Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
Experimental: SQ109 300 mg
Single daily dose of oral 300mg SQ109 for 7 days followed by 7 days washout period.
Drug: SQ109
300mg or 450mg of SQ109 administered orally, once daily for 7 days.

Detailed Description:

This is a Phase 1, randomized, single-center, clinical study of SQ109 to evaluate the potential for this drug to produce QTc prolongation. The study population is healthy male and female subjects, aged 18-45 years. Pharmacokinetics of SQ109 will be measured using interval plasma samples.The overall study design will incorporate within it a four-period investigation suitable for the QT evaluation of an active study treatment. The primary goal of the sample size considerations will be to ensure that the sample size employed during this phase of the study will be adequate to ensure a high likelihood of a successful demonstration of the QT safety of 300 and 450 mg/day SQ109. All subjects will be randomized to a sequence of three seven-day dosing periods, with each dosing period occurring once per subject. The final seven-day dosing period will occur after the first sequence of three dosing periods is completed. A washout period of at least seven days will occur between all dosing periods, and a follow-up visit will occur.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Men and women aged 18 to 45 years, inclusive.
  • Ability to understand the consent process and procedures.
  • Informed consent obtained and signed.
  • Comprehension of the study objectives and procedures which will be determined by the recruiter using a series of questions after explaining the procedures.
  • Subject agrees to be available for all study visits and is able to comply with protocol requirements for the entire duration of the study.
  • Subject agrees not to participate in another clinical trial at any time during the study period.
  • Subjects who have a body mass index (BMI) >/=18 kg/m^2 and </= 35 kg/m^2
  • General good health, without current medical illness or clinically significant abnormal physical examination findings that classify the subject as other than healthy as determined by study investigators
  • Negative serum pregnancy test at screening and a negative urine pregnancy test on the day of admittance to the inpatient phase for all female subjects of child bearing potential.
  • Negative urine toxicity screen for alcohol, marijuana, cocaine metabolite, amphetamines, opiates, PCP, barbiturates, and benzodiazepines.
  • Agreement by subjects with reproductive potential to use an adequate method of contraception during the study and for 90 days after study drug administration. Female subjects must agree to the use of two reliable methods of contraception while receiving study drug and for 90 days after study drug administration, which can include: condoms, spermicidal gel, diaphragm, hormonal or non-hormonal intrauterine device, surgical sterilization, oral contraceptive pill, and depot progesterone injections. If a male subject is heterosexually active, the subject and his partner must use at least two forms of the listed contraceptive methods.

Exclusion Criteria:

Subjects meeting any exclusion criteria at baseline will be excluded from study partcipation.

Note that individuals with a history of cardiac arrhythmias will not be included as subjects in this study.

  • Medical condition that precludes participation, including the following:

    • Hypertension with confirmed systolic blood pressure >140 mmHg or confirmed diastolic blood pressure >90 mmHg, measured after 10 - 15 minutes of rest.
    • Morbid obesity (BMI>35)
    • Current diagnosis of pulmonary disease including latent TB
    • Current diagnosis of asthma, which has required use of asthma medications within the past year
    • History of or current diagnosis of diabetes
    • Autoimmune disorder, such as lupus, Wegener's, rheumatoid arthritis
    • History of malignancy except low-grade skin cancer, (i.e., basal cell carcinoma thought to be cured)
    • Chronic renal, hepatic, or pulmonary disease condition that could interfere with the absorption of the study drug (e.g., surgical resection of significant proportions of the stomach or bowel, gastric bypass, gastric banding, irritable bowel syndrome, inflammatory bowel disease)
    • History of known Clostridium difficile infection
    • Blood donation within the previous 6 weeks
    • History of cardiac rhythm abnormality including Wolff/Parkinson/White syndrome
    • History of prolonged QT interval
    • History of allergy or photosensitivity to fluoroquinolones
  • Prolongation of QTcF interval (i.e., confirmed QTcF interval of 450 milliseconds or greater)
  • Clinically significant abnormal 12 lead electrocardiogram at screening in the judgment of the investigator, or based on the formal ECG reading; history of any cardiac abnormalities, including conduction abnormalities such as Wolff-Parkinson-White, dysrhythmias, or coronary artery disease
  • Laboratory abnormalities at Screening outside of the ranges given below. Note, if one or more screening laboratory values are outside the acceptable range on the initial screen, the abnormal test(s) may be repeated once from a single blood draw:

    • Serum creatinine (<1.1 x ULN),
    • Hemoglobin (11.0-17.5g/dL),
  • Platelet count (125,000-450,000mm^3),

    • Absolute neutrophil count (>1300 mm^3),
    • Aspartate aminotransferase (AST, </=1.2 x ULN),
    • Alanine aminotransferase (ALT, </=1.2 x ULN),
    • Proteinuria greater than trace (spot urine) and/or hematuria greater than trace.
  • Positive serology results for HIV, HBsAg, or HCV antibodies
  • Positive urine drug screen for cannabinoids, cocaine, amphetamines, opiates, benzodiazepine, barbiturates, and/or PCP.
  • Febrile illness with temperature documented >38 degrees C within 7 days of dosing.
  • Pregnancy or breastfeeding
  • Known allergic reactions to study drug components, including ingredients present in the formulation.
  • Treatment with another investigational drug within 30 days of dosing.
  • Lack of ability to fully understand the informed consent. This will be determined by the recruiter/interviewer after explaining the consent and observing the subject reading the consent.
  • Ingestion of prescription medications, over-the-counter medicines, grapefruit juice, or specific supplements in the week prior to study enrollment and during the course of the study that, in the judgment of the PI could affect the metabolism of the study drug or safety of the participant (see Concomitant Medications, Section 6.6).
  • Use of any form of tobacco, including cigarette smoking, pipe smoking, or oral tobacco; if a former smoker or tobacco user, the subject must not have used tobacco for 30 days before screening.
  • Any specific condition that, in the judgment of the Investigator, precludes participation because it could affect subject safety.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01874314

Locations
United States, Ohio
Case Western Reserve University - Case Medical Center - Infectious Disease & HIV Medicine
Cleveland, Ohio, United States, 44106-1716
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier: NCT01874314     History of Changes
Other Study ID Numbers: 11-0079, HHSN272200800026C
Study First Received: May 23, 2013
Last Updated: March 20, 2014
Health Authority: United States: Institutional Review Board
United States: Federal Government
United States: Food and Drug Administration

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
tuberculosis, SQ109, QTc, moxifloxacin, crossover, placebo, pharmacokinetic, randomized, single-center

Additional relevant MeSH terms:
Tuberculosis
Actinomycetales Infections
Bacterial Infections
Gram-Positive Bacterial Infections
Mycobacterium Infections
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Contraceptive Agents
Contraceptive Agents, Female
Contraceptives, Oral
Contraceptives, Oral, Combined
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses
Topoisomerase II Inhibitors
Topoisomerase Inhibitors

ClinicalTrials.gov processed this record on October 21, 2014